Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 12/20 | 0.47 |
| ▸ | RAF1 | P04049 | 6/20 | 0.47 |
| ▸ | BRAF | P15056 | 6/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.46 |
| ▸ | SMO | Q99835 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486377 | 0.81 | MAPK14 (0.63) | MAPK14SMOOPRK1 | |
| SCHEMBL27497392 | 0.80 | RAF1 (0.55) | MAPK14RAF1BRAFAURKAAURKB | |
| SCHEMBL27483070 | 0.80 | RAF1 (0.55) | MAPK14RAF1BRAFAURKAAURKB | |
| SCHEMBL6570490 | 0.78 | RAF1 (0.47) | MAPK14RAF1BRAFOPRK1 | |
| SCHEMBL6572676 | 0.77 | RAF1 (0.46) | MAPK14RAF1BRAFOPRK1 | |
| SCHEMBL6570486 | 0.77 | MAPK14 (0.51) | MAPK14RAF1BRAFAURKAAURKB | |
| SCHEMBL27531718 | 0.76 | RAF1 (0.49) | MAPK14RAF1BRAFAURKAAURKB | |
| SCHEMBL27554443 | 0.76 | RAF1 (0.50) | MAPK14RAF1BRAFAURKAAURKB | |
| SCHEMBL7805580 | 0.75 | MAPK14 (0.56) | MAPK14SMOOPRK1 | |
| SCHEMBL6570474 | 0.75 | MAPK14 (0.49) | MAPK14RAF1BRAFAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1077931-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | claimed |
| EP-1077931-B1 | BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES | ASTRAZENECA AB (SE) | 2004-11-17 | — | — | EP | disclosed |